This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
SNY's Subcutaneous Sarclisa Proves Non-Inferior to IV Formulation (Revised)
by Zacks Equity Research
Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
by Ekta Bagri
REGN's Eylea faces a rapid decline in sales, impacting overall performance even though Dupixent maintains momentum. We advise investors to stay on the sidelines for now.
SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study
by Zacks Equity Research
Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints
by Zacks Equity Research
DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II/III HEALEY ALS platform trial.
Sanofi Down 10% in 3 Months: How Should You Play the Stock?
by Kinjel Shah
SNY's reasonable valuation, improving top-line performance, contributions from new product launches and positive pipeline progress are good enough reasons to stay invested in the stock
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates with blockbuster potential.
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY
by Kinjel Shah
NVO's novel obesity candidate shows lower-than-expected weight loss in the study. FDA approves LLY's Zepbound for sleep apnea.
The Zacks Analyst Blog Highlights ServiceNow, AMD, Sanofi, Team and United-Guardian
by Zacks Equity Research
ServiceNow, AMD, Sanofi, Team and United-Guardian are part of the Zacks top Analyst Blog.
Top Research Reports for ServiceNow, AMD & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including ServiceNow, Inc. (NOW), Advanced Micro Devices, Inc. (AMD) and Sanofi (SNY), as well as two micro-cap stocks Team, Inc. (TISI) and United-Guardian, Inc. (UG).
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
by Zacks Equity Research
SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in infants and toddlers.
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
by Kinjel Shah
PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb study.
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts MRK's BLA for clesrovimab, its monoclonal antibody, to protect infants from RSV disease. A decision from the agency is due on June 10, 2025.
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
by Zacks Equity Research
Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.
Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?
by Zacks Equity Research
Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to Sanofi's tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis.
Regeneron Down 15.5% Year to Date: How to Play the Stock?
by Ekta Bagri
REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.
FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates
by Zacks Equity Research
The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections.
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
by Kinjel Shah
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its sales and profits to improve.
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines
by Zacks Equity Research
Novavax is working with the FDA to explore a pathway for accelerated approval of the COVID-19-flu combination and standalone flu vaccines.
Denali Starts Dosing in Phase II Parkinson's Disease Study
by Zacks Equity Research
DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.
Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M
by Zacks Equity Research
NVAX intends to use the payment from Novo to advance the development of its vaccine pipeline. The deal is expected to be closed by the end of this year.
TEVA Stock Down 10% in a Month: Should You Buy the Dip?
by Kinjel Shah
Teva's reasonable valuation, an improving pipeline, and sales and profit growth potential are good enough reasons for those who own the stock to stay invested.
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
by Zacks Equity Research
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
Top Analyst Reports for UnitedHealth, Bank of America & SAP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Bank of America Corporation (BAC) and SAP SE (SAP).